Fabry disease: Focus on cardiac manifestations and molecular mechanisms

Herz

Volumn 27, Issue 7, 2002, Pages 699-702

  Perrot, Andreas ^a   Osterziel, Karl Josef ^a   Beck, Michael ^b   Dietz, Rainer ^a   Kampmann, Christoph ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

galactosidase A deficiency; Cardiomyopathy; Enzyme replacement therapy; Fabry disease

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE;

ANHIDROSIS; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CORNEA DYSTROPHY; DRUG EFFECT; DRUG EFFICACY; EARLY DIAGNOSIS; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEMANGIOKERATOMA; HEMIZYGOSITY; HETEROZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY DISEASE; MALE; PAIN; REVIEW; SYMPTOM; VALVULAR HEART DISEASE; X CHROMOSOME LINKAGE;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; ANGINA PECTORIS; ANIMALS; ARRHYTHMIA; CARDIOMYOPATHY, HYPERTROPHIC; CELL LINE; CHILD; CRICETINAE; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; FABRY DISEASE; FEMALE; GENETIC ENGINEERING; HEART DISEASES; HEART VALVE DISEASES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ISOENZYMES; MALE; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; TIME FACTORS;

EID: 0036858794     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-002-2429-9     Document Type: Review

References (22)

1. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
2. Desnick RJ, Ioannou YA, Eng CM. a-galactosidase A deficiency: Fabry disease. In: Scriver CH, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol 3. New York: McGraw Hill, 1995:3733-74.
3. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 6o obligate carrier females. J Med Genet 2001;38:769-807.
4. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001;24:715-24.
5. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000;139:1101-8.
6. Elleder M, Bradova V, Smid F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-55.
7. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-9.
8. Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease: A histochemical and electron microscopic study. Am J Cardiol 1969;24:95-110.
9. Ikari Y, Kuwako K, Yamaguchi T. Fabry's disease with complete atrioventricular block: Histological evidence of involvement of the conduction system. Br Heart J 1992;68:323-5.
10. Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J 1977;93:699-705.
11. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975;36:829-35.
12. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986;7:1157-61.
13. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygote males. J Med Genet 2001;38:750-60.
14. Ogawa K, Sugamata K, Funamoto N, et al. Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol 1990;21:1067-73.
15. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-93.
16. Sewell AC, Böhles HJ, Perrot A, Osterziel KJ. Fabry disease as a potential cause of hypertrophic cardiomyopathy in adult men. J Inherit Metab Dis 2001;24:135.abstract.
17. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
18. Pastores GM, Lien YHH. Biochemical and molecular genetic basis of Fabry disease. J Am Soc Nephrol 2002;13:S130-3.
19. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in fabry disease: A randomized controlled trial. JAMA 2001;285:2743-9.
20. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
21. Kampmann C, Ries M, Baehner F, Kim KS, Bajbouj M, Beck M. Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertrophic infiltrative cardiomyopathy (HIC). Eur J Pediatr 2002;161:R5.abstract.
22. MacDermot K, Brown A, Jones Y, Zuckerman J. Enzyme replacement therapy reverses the cardiomyopathy of Fabry disease: results of a randomized, double-blind, placebo-controlled trial. Eur J Hum Genet 2001;92:C074.abstract.